Similar articles

• Captopril and atenolol are equally effective in retarding progression of diabetic nephropathy. Results of a 2-year prospective, randomized study.

  Elving LD, Wetzels JF, van Lier HJ, de Nobel E, Berden JH. Elving LD, et al. Diabetologia. 1994 Jun;37(6):604-9. doi: 10.1007/BF00403380. Diabetologia. 1994. PMID: 7926346 Clinical Trial.
• Long-term beneficial effect of ACE inhibition on diabetic nephropathy in normotensive type 1 diabetic patients.

  Parving HH, Hommel E, Jensen BR, Hansen HP. Parving HH, et al. Kidney Int. 2001 Jul;60(1):228-34. doi: 10.1046/j.1523-1755.2001.00790.x. Kidney Int. 2001. PMID: 11422755 Clinical Trial.
• [The effect of blood pressure-reducing therapy with captopril on tubular marker excretion in type-1 diabetics with nephropathy].

  Ratzmann KP, Raskovic M, Schimke E. Ratzmann KP, et al. Dtsch Med Wochenschr. 1994 Jun 3;119(22):796-800. doi: 10.1055/s-2008-1058763. Dtsch Med Wochenschr. 1994. PMID: 8205941 Clinical Trial. German.
• [Metabolic and hemodynamics aspects of diabetic nephropathy].

  Shestakova MV, Dedov II, Mukhin NA, Sheremet'eva OV. Shestakova MV, et al. Probl Endokrinol (Mosk). 1993 May-Jun;39(3):55-7. Probl Endokrinol (Mosk). 1993. PMID: 8058686 Review. Russian. No abstract available.
• Renoprotection in diabetes: genetic and non-genetic risk factors and treatment.

  Parving HH. Parving HH. Diabetologia. 1998 Jul;41(7):745-59. doi: 10.1007/s001250050983. Diabetologia. 1998. PMID: 9686914 Review. No abstract available.